| Ridgewood Clinics Pa | |
|
1059 Ridgewood Clinic Jackson MS 39211 | |
| (601) 957-3211 | |
| (601) 957-9753 |
| Full Name | Ridgewood Clinics Pa |
|---|---|
| Speciality | Counselor |
| Location | 1059 Ridgewood Clinic, Jackson, Mississippi |
| Authorized Official Name and Position | Krishan K. Gupta (PHYSICIAN) |
| Authorized Official Contact | 6019573211 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ridgewood Clinics Pa 1059 Ridgewood Clinic Jackson MS 39211 Ph: (601) 957-3211 | Ridgewood Clinics Pa 1059 Ridgewood Clinic Jackson MS 39211 Ph: (601) 957-3211 |
| NPI Number | 1023233749 |
|---|---|
| Provider Enumeration Date | 04/16/2007 |
| Last Update Date | 08/27/2014 |
| Medicare PECOS PAC ID | 8224029871 |
|---|---|
| Medicare Enrollment ID | O20040721000250 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023233749 | NPI | - | NPPES |
| 09013996 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 12941 (Mississippi) | Primary |
| Provider Name | Susan F Snyder |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1073573176 PECOS PAC ID: 0941214860 Enrollment ID: I20060131000356 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Provider Name | Krishan K. Gupta |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1598769176 PECOS PAC ID: 7517958176 Enrollment ID: I20120201000804 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Provider Name | Claire Tyler |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1902152937 PECOS PAC ID: 5799056032 Enrollment ID: I20170804002812 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Provider Name | Adriane Wright Harvey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811473481 PECOS PAC ID: 1557790490 Enrollment ID: I20200329000323 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Provider Name | Brandy Alexandra Rutland |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225628761 PECOS PAC ID: 1052728698 Enrollment ID: I20210329000694 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
| Provider Name | Rachael L Stout |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871366476 PECOS PAC ID: 6002250537 Enrollment ID: I20240222003554 |
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
News Archive
Although the risk of a child being admitted to hospital due to COVID-19 is small, a new UK study has found that around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection.
Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.
Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.
› Verified 5 days ago
Miracle Care Home Services Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 5120 Galaxie Dr, Suite-b, Jackson, MS 39206 Phone: 601-982-1909 Fax: 601-982-8177 | |
Chandler & Associates Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1900 Dunbarton Dr Ste J, Jackson, MS 39216 Phone: 769-428-1681 Fax: 769-241-5091 | |
Gifted Futures Ms Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6040 I-55 North Frontage Rd., Jackson, MS 39211 Phone: 929-466-1305 | |
1st Priority Healthcare Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2600 River Ridge Dr, Suite 102, Jackson, MS 39216 Phone: 252-315-5165 Fax: 888-376-1118 | |
Guided Steps Healthcare Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1900 Dunbarton Dr, Suite I, Jackson, MS 39216 Phone: 504-491-0774 Fax: 336-464-2227 | |
Marion Counseling Services, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 460 Briarwood Dr Ste 510, Jackson, MS 39206 Phone: 601-956-4816 Fax: 601-956-4816 |